Advestra on Ironwood’s USD1B Cash Tender Offer for VectivBio
Ironwood Pharmaceuticals (Nasdaq: IRWD), a healthcare company specializing in GI treatments, and VectivBio Holding (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe rare gastrointestinal conditions, have reached an agreement where Ironwood will initiate an all-cash public tender offer to acquire VectivBio at a price of USD17.00 per share. The estimated total consideration for the transaction is approximately USD1 billion, taking into account VectivBio’s cash and debt.
Advestra advised Ironwood on the Swiss legal and tax aspects of this transaction. The team included Daniel Raun (pictured), Andreas Hinsen, Anna Tomaschek, Anna Capaul, Fabian Wild, Samuel Fäh and Akira Kimati (all corporate | M&A) as well as Céline Martin, Laurent Riedweg and Philip Frey (all tax).
Homburger served as legal and tax advisor to VectivBio on the transaction. Click here for the team details.